The promise of substance P inhibitors in fibromyalgia

I. Jon Russell

Resultado de la investigación: Review articlerevisión exhaustiva

55 Citas (Scopus)


The discovery of SP and its potent biological activities have lead to the discovery of other tachykinins and to receptors for them, including the NK1 receptor. Blockade of the NK1 receptor has a number of potentially beneficial effects in medical care including the management of drug-induced emesis and the treatment of depression. The analgesic potential of NK1 receptor antagonists that, in theory, seemed so promising has not met early expectations. However, there is still reason to predict valuable clinical uses for more potent NK1 receptor antagonists in a variety of medical conditions, including FMS.

Idioma originalEnglish (US)
Páginas (desde-hasta)329-342
Número de páginas14
PublicaciónRheumatic Disease Clinics of North America
EstadoPublished - 2002

ASJC Scopus subject areas

  • Rheumatology


Profundice en los temas de investigación de 'The promise of substance P inhibitors in fibromyalgia'. En conjunto forman una huella única.

Citar esto